Targeting cancer stem cells and signaling pathways by phytochemicals: Novel approach for breast cancer therapy

Seminars in Cancer Biology

Volumn 40_41, Issue , 2016, Pages 192-208

  Dandawate, Prasad R ^a   Subramaniam, Dharmalingam ^a,b   Jensen, Roy A ^a,b   Anant, Shrikant ^a,b  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF KANSAS CANCER CENTER   (United States)

Author keywords

Breast cancer; Cancer stem cells; Curcumin; Phytochemicals; Signaling pathways

Indexed keywords

3 INDOLEMETHANOL; 3,3' DIINDOLYLMETHANE; ALPHA TOCOPHEROL; CELASTROL; CURCUMIN; EPIGALLOCATECHIN; EPIGALLOCATECHIN GALLATE; GAMMA SECRETASE INHIBITOR; GENISTEIN; ISOLIQUIRITIGENIN; JANUS KINASE; KOENIMBIN; MAMMALIAN TARGET OF RAPAMYCIN; NOTCH RECEPTOR; PARTHENOLIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PLANT MEDICINAL PRODUCT; POLYPHENOL; PROTEIN KINASE B; PTEROSTILBENE; QUERCETIN; RESVERATROL; RETINOIC ACID; SHOGAOL; SONIC HEDGEHOG PROTEIN; STAT PROTEIN; SULFORAPHANE; TRIPTOLIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; WNT PROTEIN; ANTINEOPLASTIC AGENT; PLANT EXTRACT;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; BREAST CANCER; BREAST CARCINOGENESIS; CANCER INHIBITION; CANCER RECURRENCE; CANCER STEM CELL; CELL DIFFERENTIATION; CHEMOPROPHYLAXIS; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG RESISTANCE; DRUG SELECTIVITY; DRUG SENSITIVITY; DRUG STRUCTURE; DRUG TARGETING; HUMAN; METASTASIS; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH; ANIMAL; BREAST TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFECTS; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CELL PROLIFERATION; CELL SURVIVAL; HUMANS; NEOPLASTIC STEM CELLS; PHYTOCHEMICALS; PLANT EXTRACTS; SIGNAL TRANSDUCTION;

EID: 84992217977     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2016.09.001     Document Type: Review

References (208)

1. [1] Siegel, R.L., Miller, K.D., Jemal, A., Cancer statistics, 2015. CA. Cancer J. Clin. 65 (2015), 5–29.
2. [2] Sorlie, T., Perou, C.M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. U. S. A. 98 (2001), 10869–10874.
3. [3] Sotiriou, C., Neo, S.Y., McShane, L.M., Korn, E.L., Long, P.M., Jazaeri, A., et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc. Natl. Acad. Sci. U. S. A. 100 (2003), 10393–10398.
4. [4] Isakoff, S.J., Triple-negative breast cancer: role of specific chemotherapy agents. Cancer J. 16 (2010), 53–61.
5. [5] Collina, F., Di Bonito, M., Li Bergolis, V., De Laurentiis, M., Vitagliano, C., Cerrone, M., et al. Prognostic value of cancer stem cells markers in triple-negative Breast cancer. BioMed Res. Int., 2015, 2015, 158682.
6. [6] Ginestier, C., Hur, M.H., Charafe-Jauffret, E., Monville, F., Dutcher, J., Brown, M., et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1 (2007), 555–567.
7. [7] Zinzi, L., Contino, M., Cantore, M., Capparelli, E., Leopoldo, M., Colabufo, N.A., ABC transporters in CSCs membranes as a novel target for treating tumor relapse. Front. Pharmacol., 5, 2014, 163.
8. [8] Dandawate, P., Padhye, S., Ahmad, A., Sarkar, F.H., Novel strategies targeting cancer stem cells through phytochemicals and their analogs. Drug Deliv. Transl. Res. 3 (2013), 165–182.
9. [9] Subramaniam, D., Ramalingam, S., Houchen, C.W., Anant, S., Cancer stem cells: a novel paradigm for cancer prevention and treatment. Mini Rev. Med. Chem. 10 (2010), 359–371.
10. [10] Subramaniam, D., Giridharan, P., Murmu, N., Shankaranarayanan, N.P., May, R., Houchen, C.W., et al. Activation of apoptosis by 1-hydroxy-5,7-dimethoxy-2-naphthalene-carboxaldehyde, a novel compound from Aegle marmelos. Cancer Res. 68 (2008), 8573–8581.
11. [11] Ahmed, I., Chandrakesan, P., Tawfik, O., Xia, L., Anant, S., Umar, S., Critical roles of Notch and Wnt/beta-catenin pathways in the regulation of hyperplasia and/or colitis in response to bacterial infection. Infect. Immun. 80 (2012), 3107–3121.
12. [12] Subramaniam, D., May, R., Sureban, S.M., Lee, K.B., George, R., Kuppusamy, P., et al. Diphenyl difluoroketone: a curcumin derivative with potent in vivo anticancer activity. Cancer Res. 68 (2008), 1962–1969.
13. [13] Subramaniam, D., Ponnurangam, S., Ramamoorthy, P., Standing, D., Battafarano, R.J., Anant, S., et al. Curcumin induces cell death in esophageal cancer cells through modulating Notch signaling. PLoS One, 7, 2012, e30590.
14. [14] Subramaniam, D., Ramalingam, S., Linehan, D.C., Dieckgraefe, B.K., Postier, R.G., Houchen, C.W., et al. RNA binding protein CUGBP2/CELF2 mediates curcumin-induced mitotic catastrophe of pancreatic cancer cells. PLoS One, 6, 2011, e16958.
15. [15] Kaushik, G., Kwatra, D., Subramaniam, D., Jensen, R.A., Anant, S., Mammen, J.M., Honokiol affects melanoma cell growth by targeting the AMP-activated protein kinase signaling pathway. Am. J. Surg. 208 (2014), 995–1002 discussion 1–2.
16. [16] Kaushik, G., Ramalingam, S., Subramaniam, D., Rangarajan, P., Protti, P., Rammamoorthy, P., et al. Honokiol induces cytotoxic and cytostatic effects in malignant melanoma cancer cells. Am. J. Surg. 204 (2012), 868–873.
17. [17] Kaushik, G., Venugopal, A., Ramamoorthy, P., Standing, D., Subramaniam, D., Umar, S., et al. Honokiol inhibits melanoma stem cells by targeting notch signaling. Mol. Carcinog. 54 (2015), 1710–1721.
18. [18] Vyas, A., Dandawate, P., Padhye, S., Ahmad, A., Sarkar, F., Perspectives on new synthetic curcumin analogs and their potential anticancer properties. Curr. Pharm. Des. 19 (2013), 2047–2069.
19. [19] Li, Y., Wicha, M.S., Schwartz, S.J., Sun, D., Implications of cancer stem cell theory for cancer chemoprevention by natural dietary compounds. J. Nutr. Biochem. 22 (2011), 799–806.
20. [20] Dandawate, P.R., Subramaniam, D., Padhye, S.B., Anant, S., Bitter melon: a panacea for inflammation and cancer. Chin. J. Nat. Med. 14 (2016), 81–100.
21. [21] Kwatra, D., Dandawate, P., Padhye, S., Anant, S., Bitter melon as a therapy for diabetes, inflammation, and cancer: a panacea. Curr. Pharmacol. Rep. 2 (2016), 34–44.
22. [22] Padhye, S., Dandawate, P., Yusufi, M., Ahmad, A., Sarkar, F.H., Perspectives on medicinal properties of plumbagin and its analogs. Med. Res. Rev. 32 (2012), 1131–1158.
23. [23] Pradhan, R., Dandawate, P., Vyas, A., Padhye, S., Biersack, B., Schobert, R., et al. From body art to anticancer activities: perspectives on medicinal properties of henna. Curr. Drug Targets 13 (2012), 1777–1798.
24. [24] Siddiqui, J.A., Singh, A., Chagtoo, M., Singh, N., Godbole, M.M., Chakravarti, B., Phytochemicals for breast cancer therapy: current status and future implications. Curr. Cancer Drug Targets 15 (2015), 116–135.
25. [25] Padhye, S., Chavan, D., Pandey, S., Deshpande, J., Swamy, K.V., Sarkar, F.H., Perspectives on chemopreventive and therapeutic potential of curcumin analogs in medicinal chemistry. Mini Rev. Med. Chem. 10 (2010), 372–387.
26. [26] Sahoo, K., Dozmorov, M.G., Anant, S., Awasthi, V., The curcuminoid CLEFMA selectively induces cell death in H441 lung adenocarcinoma cells via oxidative stress. Invest. New Drugs 30 (2012), 558–567.
27. [27] Dandawate, P.R., Vyas, A., Ahmad, A., Banerjee, S., Deshpande, J., Swamy, K.V., et al. Inclusion complex of novel curcumin analogue CDF and beta-cyclodextrin (1:2) and its enhanced in vivo anticancer activity against pancreatic cancer. Pharm. Res. 29 (2012), 1775–1786.
28. [28] Ronghe, A., Chatterjee, A., Singh, B., Dandawate, P., Murphy, L., Bhat, N.K., et al. Differential regulation of estrogen receptors alpha and beta by 4-(E)-{(4-hydroxyphenylimino)-methylbenzene, 1,2-diol}, a novel resveratrol analog. J. Steroid Biochem. Mol. Biol. 144:Pt B (2014), 500–512.
29. [29] Siddiqui, A., Dandawate, P., Rub, R., Padhye, S., Aphale, S., Moghe, A., et al. Novel Aza-resveratrol analogs: synthesis, characterization and anticancer activity against breast cancer cell lines. Bioorg. Med. Chem. Lett. 23 (2013), 635–640.
30. [30] Dandawate, P., Ahmad, A., Deshpande, J., Swamy, K.V., Khan, E.M., Khetmalas, M., et al. Anticancer phytochemical analogs 37: synthesis, characterization, molecular docking and cytotoxicity of novel plumbagin hydrazones against breast cancer cells. Bioorg. Med. Chem. Lett. 24 (2014), 2900–2904.
31. [31] Dandawate, P., Khan, E., Padhye, S., Gaba, H., Sinha, S., Deshpande, J., et al. Synthesis, characterization, molecular docking and cytotoxic activity of novel plumbagin hydrazones against breast cancer cells. Bioorg. Med. Chem. Lett. 22 (2012), 3104–3108.
32. [32] Padhye, S., Ahmad, A., Oswal, N., Dandawate, P., Rub, R.A., Deshpande, J., et al. Fluorinated 2’-hydroxychalcones as garcinol analogs with enhanced antioxidant and anticancer activities. Bioorg. Med. Chem. Lett. 20 (2010), 5818–5821.
33. [33] Ronghe, A., Chatterjee, A., Singh, B., Dandawate, P., Abdalla, F., Bhat, N.K., et al. 4-(E)-{(p-tolylimino)-methylbenzene2-diol}, 1 a novel resveratrol analog, differentially regulates estrogen receptors alpha and beta in breast cancer cells. Toxicol. Appl. Pharmacol., 2016, 1.
34. [34] Al-Hajj, M., Clarke, M.F., Self-renewal and solid tumor stem cells. Oncogene 23 (2004), 7274–7282.
35. [35] Boman, B.M., Wicha, M.S., Cancer stem cells: a step toward the cure. J. Clin. Oncol. 26 (2008), 2795–2799.
36. [36] Chang, W.W., Lee, C.H., Lee, P., Lin, J., Hsu, C.W., Hung, J.T., et al. Expression of Globo H and SSEA3 in breast cancer stem cells and the involvement of fucosyl transferases 1 and 2 in Globo H synthesis. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 11667–11672.
37. [37] Velasco-Velazquez, M.A., Popov, V.M., Lisanti, M.P., Pestell, R.G., The role of breast cancer stem cells in metastasis and therapeutic implications. Am. J. Pathol. 179 (2011), 2–11.
38. [38] Velasco-Velazquez, M.A., Homsi, N., De La Fuente, M., Pestell, R.G., Breast cancer stem cells. Int. J. Biochem. Cell Biol. 44 (2012), 573–577.
39. [39] Al-Hajj, M., Wicha, M.S., Benito-Hernandez, A., Morrison, S.J., Clarke, M.F., Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. U. S. A. 100 (2003), 3983–3988.
40. [40] Lawson, J.C., Blatch, G.L., Edkins, A.L., Cancer stem cells in breast cancer and metastasis. Breast Cancer Res. Treat. 118 (2009), 241–254.
41. [41] Charafe-Jauffret, E., Ginestier, C., Iovino, F., Tarpin, C., Diebel, M., Esterni, B., et al. Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. Clin. Cancer Res. 16 (2010), 45–55.
42. [42] Bi, X., Wu, C., Han, M., Cai, J., Correlations of ALDH1 expression with molecular subtypes and ABCG2 in breast cancer. Gland Surg. 1 (2012), 12–19.
43. [43] Nusse, R., Fuerer, C., Ching, W., Harnish, K., Logan, C., Zeng, A., et al. Wnt signaling and stem cell control. Cold Spring Harb. Symp. Quant. Biol. 73 (2008), 59–66.
44. [44] Tepera, S.B., McCrea, P.D., Rosen, J.M., A beta-catenin survival signal is required for normal lobular development in the mammary gland. J. Cell Sci. 116 (2003), 1137–1149.
45. [45] Li, Y., Welm, B., Podsypanina, K., Huang, S., Chamorro, M., Zhang, X., et al. Evidence that transgenes encoding components of the Wnt signaling pathway preferentially induce mammary cancers from progenitor cells. Proc. Natl. Acad. Sci. U. S. A. 100 (2003), 15853–15858.
46. [46] Lindvall, C., Evans, N.C., Zylstra, C.R., Li, Y., Alexander, C.M., Williams, B.O., The Wnt signaling receptor Lrp5 is required for mammary ductal stem cell activity and Wnt1-induced tumorigenesis. J. Biol. Chem. 281 (2006), 35081–35087.
47. [47] Liu, B.Y., McDermott, S.P., Khwaja, S.S., Alexander, C.M., The transforming activity of Wnt effectors correlates with their ability to induce the accumulation of mammary progenitor cells. Proc. Natl. Acad. Sci. U. S. A. 101 (2004), 4158–4163.
48. [48] Simoes, B.M., O'Brien, C.S., Eyre, R., Silva, A., Yu, L., Sarmiento-Castro, A., et al. Anti-estrogen resistance in human Breast tumors is driven by JAG1-NOTCH4-dependent cancer stem cell activity. Cell Rep. 12 (2015), 1968–1977.
49. [49] Hsu, E.C., Kulp, S.K., Huang, H.L., Tu, H.J., Salunke, S.B., Sullivan, N.J., et al. Function of integrin-linked kinase in modulating the stemness of IL-6-abundant breast cancer cells by regulating gamma-secretase-mediated notch1 activation in caveolae. Neoplasia (New York, NY) 17 (2015), 497–508.
50. [50] Katoh, M., Katoh, M., Integrative genomic analyses on HES/HEY family: notch-independent HES1, HES3 transcription in undifferentiated ES cells, and Notch-dependent HES1, HES5, HEY1, HEY2, HEYL transcription in fetal tissues, adult tissues, or cancer. Int. J. Oncol. 31 (2007), 461–466.
51. [51] Ronchini, C., Capobianco, A.J., Induction of cyclin D1 transcription and CDK2 activity by Notch(ic): implication for cell cycle disruption in transformation by Notch(ic). Mol. Cell. Biol. 21 (2001), 5925–5934.
52. [52] Rangarajan, A., Talora, C., Okuyama, R., Nicolas, M., Mammucari, C., Oh, H., et al. Notch signaling is a direct determinant of keratinocyte growth arrest and entry into differentiation. EMBO J. 20 (2001), 3427–3436.
53. [53] Oswald, F., Liptay, S., Adler, G., Schmid, R.M., NF-kappaB2 is a putative target gene of activated Notch-1 via RBP-Jkappa. Mol. Cell. Biol. 18 (1998), 2077–2088.
54. [54] Palomero, T., Lim, W.K., Odom, D.T., Sulis, M.L., Real, P.J., Margolin, A., et al. NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proc. Natl. Acad. Sci. U. S. A. 103 (2006), 18261–18266.
55. [55] Konishi, J., Kawaguchi, K.S., Vo, H., Haruki, N., Gonzalez, A., Carbone, D.P., et al. Gamma-secretase inhibitor prevents Notch3 activation and reduces proliferation in human lung cancers. Cancer Res. 67 (2007), 8051–8057.
56. [56] Mazzone, M., Selfors, L.M., Albeck, J., Overholtzer, M., Sale, S., Carroll, D.L., et al. Dose-dependent induction of distinct phenotypic responses to Notch pathway activation in mammary epithelial cells. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 5012–5017.
57. [57] Callahan, R., Raafat, A., Notch signaling in mammary gland tumorigenesis. J. Mammary Gland Biol. Neoplasia 6 (2001), 23–36.
58. [58] Harrison, H., Farnie, G., Howell, S.J., Rock, R.E., Stylianou, S., Brennan, K.R., et al. Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor. Cancer Res. 70 (2010), 709–718.
59. [59] Farnie, G., Clarke, R.B., Spence, K., Pinnock, N., Brennan, K., Anderson, N.G., et al. Novel cell culture technique for primary ductal carcinoma in situ: role of Notch and epidermal growth factor receptor signaling pathways. J. Natl. Cancer Inst. 99 (2007), 616–627.
60. [60] Phillips, T.M., McBride, W.H., Pajonk, F., The response of CD24(−/low)/CD44+ breast cancer-initiating cells to radiation. J. Natl. Cancer Inst. 98 (2006), 1777–1785.
61. [61] Ramasamy, T.S., Ayob, A.Z., Myint, H.H., Thiagarajah, S., Amini, F., Targeting colorectal cancer stem cells using curcumin and curcumin analogues: insights into the mechanism of the therapeutic efficacy. Cancer Cell Int., 15, 2015, 96.
62. [62] Stanger, B.Z., Quit your YAPing: a new target for cancer therapy. Genes Dev. 26 (2012), 1263–1267.
63. [63] Steinhardt, A.A., Gayyed, M.F., Klein, A.P., Dong, J., Maitra, A., Pan, D., et al. Expression of Yes-associated protein in common solid tumors. Hum. Pathol. 39 (2008), 1582–1589.
64. [64] Avruch, J., Zhou, D., Fitamant, J., Bardeesy, N., Mou, F., Barrufet, L.R., Protein kinases of the Hippo pathway: regulation and substrates. Semin. Cell Dev. Biol. 23 (2012), 770–784.
65. [65] Overholtzer, M., Zhang, J., Smolen, G.A., Muir, B., Li, W., Sgroi, D.C., et al. Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc. Natl. Acad. Sci. U. S. A. 103 (2006), 12405–12410.
66. [66] Chan, S.W., Lim, C.J., Guo, K., Ng, C.P., Lee, I., Hunziker, W., et al. A role for TAZ in migration, invasion, and tumorigenesis of breast cancer cells. Cancer Res. 68 (2008), 2592–2598.
67. [67] Cordenonsi, M., Zanconato, F., Azzolin, L., Forcato, M., Rosato, A., Frasson, C., et al. The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell 147 (2011), 759–772.
68. [68] Radisky, D.C., LaBarge, M.A., Epithelial-mesenchymal transition and the stem cell phenotype. Cell Stem Cell 2 (2008), 511–512.
69. [69] Hanahan, D., Weinberg, R.A., Hallmarks of cancer: the next generation. Cell 144 (2011), 646–674.
70. [70] Hao, J., Zhang, Y., Wang, Y., Ye, R., Qiu, J., Zhao, Z., et al. Role of extracellular matrix and YAP/TAZ in cell fate determination. Cell. Signal. 26 (2014), 186–191.
71. [71] Zhang, X., Harrington, N., Moraes, R.C., Wu, M.F., Hilsenbeck, S.G., Lewis, M.T., Cyclopamine inhibition of human breast cancer cell growth independent of Smoothened (Smo). Breast Cancer Res. Treat. 115 (2009), 505–521.
72. [72] Kameda, C., Tanaka, H., Yamasaki, A., Nakamura, M., Koga, K., Sato, N., et al. The Hedgehog pathway is a possible therapeutic target for patients with estrogen receptor-negative breast cancer. Anticancer Res. 29 (2009), 871–879.
73. [73] Michno, K., Boras-Granic, K., Mill, P., Hui, C.C., Hamel, P.A., Shh expression is required for embryonic hair follicle but not mammary gland development. Dev. Biol. 264 (2003), 153–165.
74. [74] Lee, M.Y., Sun, L., Veltmaat, J.M., Hedgehog and Gli signaling in embryonic mammary gland development. J. Mammary Gland Biol. Neoplasia 18 (2013), 133–138.
75. [75] Moraes, R.C., Zhang, X., Harrington, N., Fung, J.Y., Wu, M.F., Hilsenbeck, S.G., et al. Constitutive activation of smoothened (SMO) in mammary glands of transgenic mice leads to increased proliferation, altered differentiation and ductal dysplasia. Development (Cambridge, England) 134 (2007), 1231–1242.
76. [76] Jeng, K.S., Sheen, I.S., Jeng, W.J., Yu, M.C., Hsiau, H.I., Chang, F.Y., High expression of Sonic Hedgehog signaling pathway genes indicates a risk of recurrence of breast carcinoma. OncoTargets Ther. 7 (2013), 79–86.
77. [77] Garcia-Zaragoza, E., Perez-Tavarez, R., Ballester, A., Lafarga, V., Jimenez-Reinoso, A., Ramirez, A., et al. Intraepithelial paracrine Hedgehog signaling induces the expansion of ciliated cells that express diverse progenitor cell markers in the basal epithelium of the mouse mammary gland. Dev. Biol. 372 (2012), 28–44.
78. [78] Thomas, Z.I., Gibson, W., Sexton, J.Z., Aird, K.M., Ingram, S.M., Aldrich, A., et al. Targeting GLI1 expression in human inflammatory breast cancer cells enhances apoptosis and attenuates migration. Br. J. Cancer 104 (2011), 1575–1586.
79. [79] Fiaschi, M., Rozell, B., Bergstrom, A., Toftgard, R., Development of mammary tumors by conditional expression of GLI1. Cancer Res. 69 (2009), 4810–4817.
80. [80] Liu, S., Dontu, G., Mantle, I.D., Patel, S., Ahn, N.S., Jackson, K.W., et al. Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res. 66 (2006), 6063–6071.
81. [81] Thomas, S.J., Snowden, J.A., Zeidler, M.P., Danson, S.J., The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours. Br. J. Cancer 113 (2015), 365–371.
82. [82] Kiger, A.A., Jones, D.L., Schulz, C., Rogers, M.B., Fuller, M.T., Stem cell self-renewal specified by JAK-STAT activation in response to a support cell cue. Science 294 (2001), 2542–2545.
83. [83] Hernandez-Vargas, H., Ouzounova, M., Le Calvez-Kelm, F., Lambert, M.P., McKay-Chopin, S., Tavtigian, S.V., et al. Methylome analysis reveals Jak-STAT pathway deregulation in putative breast cancer stem cells. Epigenetics 6 (2011), 428–439.
84. [84] Porta, C., Paglino, C., Mosca, A., Targeting PI3K/Akt/mTOR signaling in cancer. Front. Oncol., 4, 2014, 64.
85. [85] Steelman, L.S., Abrams, S.L., Whelan, J., Bertrand, F.E., Ludwig, D.E., Basecke, J., et al. Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia. Leukemia 22 (2008), 686–707.
86. [86] Xia, P., Xu, X.Y., PI3K/Akt/mTOR signaling pathway in cancer stem cells: from basic research to clinical application. Am. J. Cancer. Res. 5 (2015), 1602–1609.
87. [87] Zhou, J., Wulfkuhle, J., Zhang, H., Gu, P., Yang, Y., Deng, J., et al. Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc. Natl. Acad. Sci. U. S. A. 104 (2007), 16158–16163.
88. [88] Wang, J., Zhu, R., Sun, D., Sun, X., Geng, Z., Liu, H., et al. Intracellular uptake of curcumin-loaded solid lipid nanoparticles exhibit anti-inflammatory activities superior to those of curcumin through the NF-kappaB signaling pathway. J. Biomed. Nanotechnol. 11 (2015), 403–415.
89. [89] Jin, H., Qiao, F., Wang, Y., Xu, Y., Shang, Y., Curcumin inhibits cell proliferation and induces apoptosis of human non-small cell lung cancer cells through the upregulation of miR-192-5p and suppression of PI3K/Akt signaling pathway. Oncol. Rep. 34 (2015), 2782–2789.
90. [90] Nabavi, S.F., Thiagarajan, R., Rastrelli, L., Daglia, M., Sobarzo-Sanchez, E., Alinezhad, H., et al. Curcumin: a natural product for diabetes and its complications. Curr. Top. Med. Chem. 15 (2015), 2445–2455.
91. [91] Cojocneanu Petric, R., Braicu, C., Raduly, L., Zanoaga, O., Dragos, N., Monroig, P., et al. Phytochemicals modulate carcinogenic signaling pathways in breast and hormone-related cancers. OncoTargets Ther. 8 (2015), 2053–2066.
92. [92] Kim, S.-H., Sehrawat, A., Singh, S.V., Dietary chemopreventative benzyl isothiocyanate inhibits Breast cancer stem cells in vitro and in vivo. Cancer Prev. Res. (Philadelphia, Pa) 6 (2013), 782–790.
93. [93] Fu, Y., Chang, H., Peng, X., Bai, Q., Yi, L., Zhou, Y., et al. Resveratrol inhibits breast cancer stem-like cells and induces autophagy via suppressing Wnt/beta-catenin signaling pathway. PLoS One, 9, 2014, e102535.
94. [94] Abdel-Daim, M.M., Abdou, R.H., Protective effects of diallyl sulfide and curcumin separately against thallium-induced toxicity in rats. Cell J. 17 (2015), 379–388.
95. [95] Epelbaum, R., Schaffer, M., Vizel, B., Badmaev, V., Bar-Sela, G., Curcumin and gemcitabine in patients with advanced pancreatic cancer. Nutr. Cancer 62 (2010), 1137–1141.
96. [96] Chauhan, D.P., Chemotherapeutic potential of curcumin for colorectal cancer. Curr. Pharm. Des. 8 (2002), 1695–1706.
97. [97] Khazaei Koohpar, Z., Entezari, M., Movafagh, A., Hashemi, M., Anticancer activity of curcumin on human breast adenocarcinoma: role of Mcl-1 gene. Iran. J. Cancer Prev., 8, 2015, e2331.
98. [98] Chen, Q.H., Curcumin-based anti-prostate cancer agents. Anticancer Agents Med. Chem. 15 (2015), 138–156.
99. [99] Liu, H.S., Ke, C.S., Cheng, H.C., Huang, C.Y., Su, C.L., Curcumin-induced mitotic spindle defect and cell cycle arrest in human bladder cancer cells occurs partly through inhibition of aurora A. Mol. Pharmacol. 80 (2011), 638–646.
100. [100] Nagaraju, G.P., Aliya, S., Zafar, S.F., Basha, R., Diaz, R., El-Rayes, B.F., The impact of curcumin on breast cancer. Integr. Biol.: Quant. Biosci. nano macro 4 (2012), 996–1007.
101. [101] Hani, U., Shivakumar, H.G., Solubility enhancement and delivery systems of curcumin an herbal medicine: a review. Curr. Drug Deliv. 11 (2014), 792–804.
102. [102] Padhye, S., Banerjee, S., Chavan, D., Pandye, S., Swamy, K.V., Ali, S., et al. Fluorocurcumins as cyclooxygenase-2 inhibitor: molecular docking, pharmacokinetics and tissue distribution in mice. Pharm. Res. 26 (2009), 2438–2445.
103. [103] Lin, L., Hutzen, B., Zuo, M., Ball, S., Deangelis, S., Foust, E., et al. Novel STAT3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreatic and breast cancer cells. Cancer Res. 70 (2010), 2445–2454.
104. [104] Lin, L., Liu, Y., Li, H., Li, P.K., Fuchs, J., Shibata, H., et al. Targeting colon cancer stem cells using a new curcumin analogue, GO-Y030. Br. J. Cancer 105 (2011), 212–220.
105. [105] Subramaniam, D., Nicholes, N.D., Dhar, A., Umar, S., Awasthi, V., Welch, D.R., et al. 3,5-bis(2,4-difluorobenzylidene)-4-piperidone, a novel compound that affects pancreatic cancer growth and angiogenesis. Mol. Cancer Ther. 10 (2011), 2146–2156.
106. [106] Liu, D., Chen, Z., The effect of curcumin on breast cancer cells. J. Breast Cancer 16 (2013), 133–137.
107. [107] Sinha, D., Biswas, J., Sung, B., Aggarwal, B.B., Bishayee, A., Chemopreventive and chemotherapeutic potential of curcumin in breast cancer. Curr. Drug Targets 13 (2012), 1799–1819.
108. [108] Mukherjee, S., Mazumdar, M., Chakraborty, S., Manna, A., Saha, S., Khan, P., et al. Curcumin inhibits breast cancer stem cell migration by amplifying the E-cadherin/beta-catenin negative feedback loop. Stem Cell Res. Ther., 5, 2014, 116.
109. [109] Kakarala, M., Brenner, D.E., Korkaya, H., Cheng, C., Tazi, K., Ginestier, C., et al. Targeting breast stem cells with the cancer preventive compounds curcumin and piperine. Breast Cancer Res. Treat. 122 (2010), 777–785.
110. [110] Charpentier, M.S., Whipple, R.A., Vitolo, M.I., Boggs, A.E., Slovic, J., Thompson, K.N., et al. Curcumin targets breast cancer stem-like cells with microtentacles that persist in mammospheres and promote reattachment. Cancer Res. 74 (2014), 1250–1260.
111. [111] Strofer, M., Jelkmann, W., Depping, R., Curcumin decreases survival of Hep3 B liver and MCF-7 breast cancer cells: the role of HIF. Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft [et al] 187 (2011), 393–400.
112. [112] Li, Y., Revalde, J.L., Reid, G., Paxton, J.W., Interactions of dietary phytochemicals with ABC transporters: possible implications for drug disposition and multidrug resistance in cancer. Drug Metab. Rev. 42 (2010), 590–611.
113. [113] Chung, S.S., Vadgama, J.V., Curcumin and epigallocatechin gallate inhibit the cancer stem cell phenotype via down-regulation of STAT3-NFkappaB signaling. Anticancer Res. 35 (2015), 39–46.
114. [114] Zhou, Q., Ye, M., Lu, Y., Zhang, H., Chen, Q., Huang, S., et al. Curcumin improves the tumoricidal effect of mitomycin C by suppressing ABCG2 expression in stem cell-Like Breast cancer cells. PLoS One, 10, 2015, e0136694.
115. [115] Gulcur, E., Thaqi, M., Khaja, F., Kuzmis, A., Onyuksel, H., Curcumin in VIP-targeted sterically stabilized phospholipid nanomicelles: a novel therapeutic approach for breast cancer and breast cancer stem cells. Drug Deliv. Transl. Res., 3, 2013.
116. [116] Wei, X., Senanayake, T.H., Warren, G., Vinogradov, S.V., Hyaluronic acid-based nanogel-drug conjugates with enhanced anticancer activity designed for the targeting of CD44-positive and drug-resistant tumors. Bioconjugate Chem. 24 (2013), 658–668.
117. [117] Bishayee, A., Cancer prevention and treatment with resveratrol: from rodent studies to clinical trials. Cancer Prev. Res. (Phila.) 2 (2009), 409–418.
118. [118] Langcake, P., Pryce, R.J., The production of resveratrol by Vitis vinifera and other members of the Vitaceae as a response to infection or injury. Physiol. Plant Pathol. 9 (1976), 77–86.
119. [119] Vastano, B.C., Chen, Y., Zhu, N., Ho, C.T., Zhou, Z., Rosen, R.T., Isolation and identification of stilbenes in two varieties of Polygonum cuspidatum. J. Agric. Food Chem. 48 (2000), 253–256.
120. [120] Renaud, S., de Lorgeril, M., Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet (London, England) 339 (1992), 1523–1526.
121. [121] Resveratrol, Pervaiz S., from grapevines to mammalian biology. FASEB J. 17 (2003), 1975–1985.
122. [122] Carter, L.G., D'Orazio, J.A., Pearson, K.J., Resveratrol and cancer: focus on in vivo evidence. Endocr. Relat. Cancer 21 (2014), R209–25.
123. [123] Banerjee, S., Bueso-Ramos, C., Aggarwal, B.B., Suppression of 7,12-dimethylbenz(a)anthracene-induced mammary carcinogenesis in rats by resveratrol: role of nuclear factor-kappaB, cyclooxygenase 2, and matrix metalloprotease 9. Cancer Res. 62 (2002), 4945–4954.
124. [124] Sato, M., Pei, R.J., Yuri, T., Danbara, N., Nakane, Y., Tsubura, A., Prepubertal resveratrol exposure accelerates N-methyl-N-nitrosourea-induced mammary carcinoma in female Sprague-Dawley rats. Cancer Lett. 202 (2003), 137–145.
125. [125] Garvin, S., Ollinger, K., Dabrosin, C., Resveratrol induces apoptosis and inhibits angiogenesis in human breast cancer xenografts in vivo. Cancer Lett. 231 (2006), 113–122.
126. [126] Provinciali, M., Re, F., Donnini, A., Orlando, F., Bartozzi, B., Di Stasio, G., et al. Effect of resveratrol on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Int. J. Cancer 115 (2005), 36–45.
127. [127] Seino, M., Okada, M., Shibuya, K., Seino, S., Suzuki, S., Takeda, H., et al. Differential contribution of ROS to resveratrol-induced cell death and loss of self-renewal capacity of ovarian cancer stem cells. Anticancer Res. 35 (2015), 85–96.
128. [128] Pandey, P.R., Okuda, H., Watabe, M., Pai, S.K., Liu, W., Kobayashi, A., et al. Resveratrol suppresses growth of cancer stem-like cells by inhibiting fatty acid synthase. Breast Cancer Res. Treat. 130 (2011), 387–398.
129. [129] Pandey, P.R., Xing, F., Sharma, S., Watabe, M., Pai, S.K., Iiizumi-Gairani, M., et al. Elevated lipogenesis in epithelial stem-like cell confers survival advantage in ductal carcinoma in situ of breast cancer. Oncogene 32 (2013), 5111–5122.
130. [130] Shimono, Y., Mukohyama, J., Nakamura, S., Minami, H., MicroRNA regulation of human breast cancer stem cells. J. Clin. Med., 2015, 2015.
131. [131] Hagiwara, K., Kosaka, N., Yoshioka, Y., Takahashi, R.U., Takeshita, F., Ochiya, T., Stilbene derivatives promote Ago2-dependent tumour-suppressive microRNA activity. Sci. Rep., 2, 2012, 314.
132. [132] Tsai, J.H., Hsu, L.S., Lin, C.L., Hong, H.M., Pan, M.H., Way, T.D., et al. 3,5,4’-trimethoxystilbene, a natural methoxylated analog of resveratrol, inhibits breast cancer cell invasiveness by downregulation of PI3K/Akt and Wnt/beta-catenin signaling cascades and reversal of epithelial-mesenchymal transition. Toxicol. Appl. Pharmacol. 272 (2013), 746–756.
133. [133] Mukhtar, H., Ahmad, N., Tea polyphenols: prevention of cancer and optimizing health. Am. J. Clin. Nutr. 71 (2000), 1698S–1702S discussion 703S-4S.
134. [134] Kanwar, J., Taskeen, M., Mohammad, I., Huo, C., Chan, T.H., Dou, Q.P., Recent advances on tea polyphenols. Front. Biosci. (Elite edition) 4 (2012), 111–131.
135. [135] Hou, I.C., Amarnani, S., Chong, M.T., Bishayee, A., Green tea and the risk of gastric cancer: epidemiological evidence. World J. Gastroenterol. 19 (2013), 3713–3722.
136. [136] Darvesh, A.S., Bishayee, A., Chemopreventive and therapeutic potential of tea polyphenols in hepatocellular cancer. Nutr. Cancer 65 (2013), 329–344.
137. [137] Li, M.J., Yin, Y.C., Wang, J., Jiang, Y.F., Green tea compounds in breast cancer prevention and treatment. World J. Clin. Oncol. 5 (2014), 520–528.
138. [138] Gu, J.W., Makey, K.L., Tucker, K.B., Chinchar, E., Mao, X., Pei, I., et al. EGCG, a major green tea catechin suppresses breast tumor angiogenesis and growth via inhibiting the activation of HIF-1alpha and NFkappaB, and VEGF expression. Vasc. Cell, 5, 2013, 9.
139. [139] Mineva, N.D., Paulson, K.E., Naber, S.P., Yee, A.S., Sonenshein, G.E., Epigallocatechin-3-gallate inhibits stem-like inflammatory breast cancer cells. PLoS One, 8, 2013, e73464.
140. [140] Sarkar, F.H., Li, Y., Wang, Z., Kong, D., The role of nutraceuticals in the regulation of Wnt and Hedgehog signaling in cancer. Cancer Metastasis Rev. 29 (2010), 383–394.
141. [141] Choudhary, S., Sood, S., Donnell, R.L., Wang, H.C., Intervention of human breast cell carcinogenesis chronically induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. Carcinogenesis 33 (2012), 876–885.
142. [142] Chen, D., Pamu, S., Cui, Q., Chan, T.H., Dou, Q.P., Novel epigallocatechin gallate (EGCG) analogs activate AMP-activated protein kinase pathway and target cancer stem cells. Bioorgan. Med. Chem. 20 (2012), 3031–3037.
143. [143] Latte, K.P., Appel, K.E., Lampen, A., Health benefits and possible risks of broccoli – an overview. Food Chem. Toxicol. 49 (2011), 3287–3309.
144. [144] Herr, I., Buchler, M.W., Dietary constituents of broccoli and other cruciferous vegetables: implications for prevention and therapy of cancer. Cancer Treat. Rev. 36 (2010), 377–383.
145. [145] Gupta, P., Wright, S.E., Kim, S.H., Srivastava, S.K., Phenethyl isothiocyanate: a comprehensive review of anti-cancer mechanisms. Biochim. Biophys. Acta 1846 (2014), 405–424.
146. [146] Zhang, Y., Tang, L., Discovery and development of sulforaphane as a cancer chemopreventive phytochemical. Acta Pharmacol. Sin. 28 (2007), 1343–1354.
147. [147] Wattenberg, L.W., Inhibition of carcinogenic effects of polycyclic hydrocarbons by benzyl isothiocyanate and related compounds. J. Natl. Cancer Inst. 58 (1977), 395–398.
148. [148] Meeran, S.M., Patel, S.N., Li, Y., Shukla, S., Tollefsbol, T.O., Bioactive dietary supplements reactivate ER expression in ER-negative breast cancer cells by active chromatin modifications. PLoS One, 7, 2012, e37748.
149. [149] Kanematsu, S., Uehara, N., Miki, H., Yoshizawa, K., Kawanaka, A., Yuri, T., et al. Autophagy inhibition enhances sulforaphane-induced apoptosis in human breast cancer cells. Anticancer Res. 30 (2010), 3381–3390.
150. [150] Kim, H.N., Kim, D.H., Kim, E.H., Lee, M.H., Kundu, J.K., Na, H.K., et al. Sulforaphane inhibits phorbol ester-stimulated IKK-NF-kappaB signaling and COX-2 expression in human mammary epithelial cells by targeting NF-kappaB activating kinase and ERK. Cancer Lett. 351 (2014), 41–49.
151. [151] Lee, Y.R., Noh, E.M., Han, J.H., Kim, J.M., Hwang, B.M., Kim, B.S., et al. Sulforaphane controls TPA-induced MMP-9 expression through the NF-kappaB signaling pathway, but not AP-1, in MCF-7 breast cancer cells. BMB Rep. 46 (2013), 201–206.
152. [152] Li, Y., Zhang, T., Korkaya, H., Liu, S., Lee, H.F., Newman, B., et al. Sulforaphane, a dietary component of broccoli/broccoli sprouts, inhibits breast cancer stem cells. Clin. Cancer Res. 16 (2010), 2580–2590.
153. [153] Li, Q., Yao, Y., Eades, G., Liu, Z., Zhang, Y., Zhou, Q., Downregulation of miR-140 promotes cancer stem cell formation in basal-like early stage breast cancer. Oncogene 33 (2014), 2589–2600.
154. [154] Li, Q., Eades, G., Yao, Y., Zhang, Y., Zhou, Q., Characterization of a stem-like subpopulation in basal-like ductal carcinoma in situ (DCIS) lesions. J. Biol. Chem. 289 (2014), 1303–1312.
155. [155] Hunakova, L., Sedlakova, O., Cholujova, D., Gronesova, P., Duraj, J., Sedlak, J., Modulation of markers associated with aggressive phenotype in MDA-MB-231 breast carcinoma cells by sulforaphane. Neoplasma 56 (2009), 548–556.
156. [156] Weng, J.R., Tsai, C.H., Kulp, S.K., Chen, C.S., Indole-3-carbinol as a chemopreventive and anti-cancer agent. Cancer Lett. 262 (2008), 153–163.
157. [157] Tin, A.S., Park, A.H., Sundar, S.N., Firestone, G.L., Essential role of the cancer stem/progenitor cell marker nucleostemin for indole-3-carbinol anti-proliferative responsiveness in human breast cancer cells. BMC Biol., 12, 2014, 72.
158. [158] Ahmad, A., Ali, S., Ahmed, A., Ali, A.S., Raz, A., Sakr, W.A., et al. 3, 3’-Diindolylmethane enhances the effectiveness of herceptin against HER-2/neu-expressing breast cancer cells. PLoS One, 8, 2013, e54657.
159. [159] Jin, Y., 3,3’-Diindolylmethane inhibits breast cancer cell growth via miR-21-mediated Cdc25A degradation. Mol. Cell. Biochem. 358 (2011), 345–354.
160. [160] Mahmoud, A.M., Yang, W., Bosland, M.C., Soy isoflavones and prostate cancer: a review of molecular mechanisms. J. Steroid Biochem. Mol. Biol. 140 (2014), 116–132.
161. [161] Martin, P.M., Horwitz, K.B., Ryan, D.S., McGuire, W.L., Phytoestrogen interaction with estrogen receptors in human breast cancer cells. Endocrinology 103 (1978), 1860–1867.
162. [162] Jacobsen, B.K., Knutsen, S.F., Fraser, G.E., Does high soy milk intake reduce prostate cancer incidence? The Adventist Health Study (United States). Cancer Causes Control: CCC 9 (1998), 553–557.
163. [163] Fan, P., Fan, S., Wang, H., Mao, J., Shi, Y., Ibrahim, M.M., et al. Genistein decreases the breast cancer stem-like cell population through Hedgehog pathway. Stem Cell Res. Ther., 4, 2013, 146.
164. [164] Montales, M.T., Rahal, O.M., Nakatani, H., Matsuda, T., Simmen, R.C., Repression of mammary adipogenesis by genistein limits mammosphere formation of human MCF-7 cells. J. Endocrinol. 218 (2013), 135–149.
165. [165] Montales, M.T., Rahal, O.M., Kang, J., Rogers, T.J., Prior, R.L., Wu, X., et al. Repression of mammosphere formation of human breast cancer cells by soy isoflavone genistein and blueberry polyphenolic acids suggests diet-mediated targeting of cancer stem-like/progenitor cells. Carcinogenesis 33 (2012), 652–660.
166. [166] Brigelius-Flohe, R., Traber, M.G., Vitamin E. function and metabolism. FASEB J. 13 (1999), 1145–1155.
167. [167] Gopalan, A., Yu, W., Sanders, B.G., Kline, K., Eliminating drug resistant breast cancer stem-like cells with combination of simvastatin and gamma-tocotrienol. Cancer Lett. 328 (2013), 285–296.
168. [168] Yan, B., Stantic, M., Zobalova, R., Bezawork-Geleta, A., Stapelberg, M., Stursa, J., et al. Mitochondrially targeted vitamin E succinate efficiently kills breast tumour-initiating cells in a complex II-dependent manner. BMC Cancer, 15, 2015, 401.
169. [169] Stapelberg, M., Zobalova, R., Nguyen, M.N., Walker, T., Stantic, M., Goodwin, J., et al. Indoleamine-2,3-dioxygenase elevated in tumor-initiating cells is suppressed by mitocans. Free Radic. Biol. Med. 67 (2014), 41–50.
170. [170] Wolf, G., Is 9-cis-retinoic acid the endogenous ligand for the retinoic acid-X receptor. Nutr. Rev. 64 (2006), 532–538.
171. [171] Duester, G., Retinoic acid synthesis and signaling during early organogenesis. Cell 134 (2008), 921–931.
172. [172] Garattini, E., Gianni, M., Terao, M., Cytodifferentiation by retinoids, a novel therapeutic option in oncology: rational combinations with other therapeutic agents. Vitam. Horm. 75 (2007), 301–354.
173. [173] de The, H., Chen, Z., Acute promyelocytic leukaemia: novel insights into the mechanisms of cure. Nat. Rev. Cancer 10 (2010), 775–783.
174. [174] Baumrucker, C.R., Schanbacher, F., Shang, Y., Green, M.H., Lactoferrin interaction with retinoid signaling: cell growth and apoptosis in mammary cells. Domest. Anim. Endocrinol. 30 (2006), 289–303.
175. [175] Lu, M., Mira-y-Lopez, R., Nakajo, S., Nakaya, K., Jing, Y., Expression of estrogen receptor alpha, retinoic acid receptor alpha and cellular retinoic acid binding protein II genes is coordinately regulated in human breast cancer cells. Oncogene 24 (2005), 4362–4369.
176. [176] Cicatiello, L., Mutarelli, M., Grober, O.M., Paris, O., Ferraro, L., Ravo, M., et al. Estrogen receptor alpha controls a gene network in luminal-like breast cancer cells comprising multiple transcription factors and microRNAs. Am. J. Pathol. 176 (2010), 2113–2130.
177. [177] Paroni, G., Fratelli, M., Gardini, G., Bassano, C., Flora, M., Zanetti, A., et al. Synergistic antitumor activity of lapatinib and retinoids on a novel subtype of breast cancer with coamplification of ERBB2 and RARA. Oncogene 31 (2012), 3431–3443.
178. [178] Bhat-Nakshatri, P., Goswami, C.P., Badve, S., Sledge, G.W. Jr., Nakshatri, H., Identification of FDA-approved drugs targeting breast cancer stem cells along with biomarkers of sensitivity. Sci. Rep., 3, 2013, 2530.
179. [179] Papi, A., Guarnieri, T., Storci, G., Santini, D., Ceccarelli, C., Taffurelli, M., et al. Nuclear receptors agonists exert opposing effects on the inflammation dependent survival of breast cancer stem cells. Cell Death Differ. 19 (2012), 1208–1219.
180. [180] Croker, A.K., Allan, A.L., Inhibition of aldehyde dehydrogenase (ALDH) activity reduces chemotherapy and radiation resistance of stem-like ALDHhiCD44(+) human breast cancer cells. Breast Cancer Res. Treat. 133 (2012), 75–87.
181. [181] Berardi, D.E., Flumian, C., Campodonico, P.B., Urtreger, A.J., Diaz Bessone, M.I., Motter, A.N., et al. Myoepithelial and luminal breast cancer cells exhibit different responses to all-trans retinoic acid. Cell. Oncol. (Dordrecht) 38 (2015), 289–305.
182. [182] Wang, B., Wang, Q., Wang, Z., Jiang, J., Yu, S.C., Ping, Y.F., et al. Metastatic consequences of immune escape from NK cell cytotoxicity by human breast cancer stem cells. Cancer Res. 74 (2014), 5746–5757.
183. [183] Li, R.J., Ying, X., Zhang, Y., Ju, R.J., Wang, X.X., Yao, H.J., et al. All-trans retinoic acid stealth liposomes prevent the relapse of breast cancer arising from the cancer stem cells. J. Control. Rel. 149 (2011), 281–291.
184. [184] Wei, L., Liu, T.T., Wang, H.H., Hong, H.M., Yu, A.L., Feng, H.P., et al. Hsp27 participates in the maintenance of breast cancer stem cells through regulation of epithelial-mesenchymal transition and nuclear factor-kappaB. Breast Cancer Res.: BCR, 13, 2011, R101.
185. [185] Lee, C.H., Wu, Y.T., Hsieh, H.C., Yu, Y., Yu, A.L., Chang, W.W., Epidermal growth factor/heat shock protein 27 pathway regulates vasculogenic mimicry activity of breast cancer stem/progenitor cells. Biochimie 104 (2014), 117–126.
186. [186] Lee, C.H., Hong, H.M., Chang, Y.Y., Chang, W.W., Inhibition of heat shock protein (Hsp) 27 potentiates the suppressive effect of Hsp90 inhibitors in targeting breast cancer stem-like cells. Biochimie 94 (2012), 1382–1389.
187. [187] Zhou, J., Zhang, H., Gu, P., Bai, J., Margolick, J.B., Zhang, Y., NF-kappaB pathway inhibitors preferentially inhibit breast cancer stem-like cells. Breast Cancer Res. Treat. 111 (2008), 419–427.
188. [188] Liu, Y., Lu, W.L., Guo, J., Du, J., Li, T., Wu, J.W., et al. A potential target associated with both cancer and cancer stem cells: a combination therapy for eradication of breast cancer using vinorelbine stealthy liposomes plus parthenolide stealthy liposomes. J. Control. Rel. 129 (2008), 18–25.
189. [189] Li, J., Liu, R., Yang, Y., Huang, Y., Li, X., Liu, R., et al. Triptolide-induced in vitro and in vivo cytotoxicity in human breast cancer stem cells and primary breast cancer cells. Oncogene 31 (2014), 2181–2186.
190. [190] Sarkar, T.R., Battula, V.L., Werden, S.J., Vijay, G.V., Ramirez-Pena, E.Q., Taube, J.H., et al. GD3 synthase regulates epithelial-mesenchymal transition and metastasis in breast cancer. Oncogene 34 (2015), 2958–2967.
191. [191] Ray, A., Vasudevan, S., Sengupta, S., 6-Shogaol inhibits breast cancer cells and stem cell-like spheroids by modulation of notch signaling pathway and induction of autophagic cell death. PLoS One, 10, 2015, e0137614.
192. [192] Wu, C.H., Hong, B.H., Ho, C.T., Yen, G.C., Targeting cancer stem cells in breast cancer: potential anticancer properties of 6-shogaol and pterostilbene. J. Agric. Food Chem. 63 (2015), 2432–2441.
193. [193] Mak, K.K., Wu, A.T., Lee, W.H., Chang, T.C., Chiou, J.F., Wang, L.S., et al. Pterostilbene, a bioactive component of blueberries, suppresses the generation of breast cancer stem cells within tumor microenvironment and metastasis via modulating NF-kappaB/microRNA 448 circuit. Mol. Nutr. Food Res. 57 (2013), 1123–1134.
194. [194] Wang, N., Wang, Z., Wang, Y., Xie, X., Shen, J., Peng, C., et al. Dietary compound isoliquiritigenin prevents mammary carcinogenesis by inhibiting breast cancer stem cells through WIF1 demethylation. Oncotarget 6 (2015), 9854–9876.
195. [195] Ahmadipour, F., Noordin, M.I., Mohan, S., Arya, A., Paydar, M., Looi, C.Y., et al. Koenimbin, a natural dietary compound of Murraya koenigii (L) Spreng: inhibition of MCF7 breast cancer cells and targeting of derived MCF7 breast cancer stem cells (CD44(+)/CD24(-/low)): an in vitro study. Drug Design Dev. Ther. 9 (2015), 1193–1208.
196. [196] Chen, J.K., Taipale, J., Young, K.E., Maiti, T., Beachy, P.A., Small molecule modulation of Smoothened activity. Proc. Natl. Acad. Sci. U. S. A. 99 (2002), 14071–14076.
197. [197] Huang, Y.C., Chao, K.S., Liao, H.F., Chen, Y.J., Targeting sonic hedgehog signaling by compounds and derivatives from natural products. Evid.-Based Complement. Altern. Med.: eCAM, 2013, 2013, 748587.
198. [198] Luo, G., Long, J., Cui, X., Xiao, Z., Liu, Z., Shi, S., et al. Highly lymphatic metastatic pancreatic cancer cells possess stem cell-like properties. Int. J. Oncol. 42 (2013), 979–984.
199. [199] Liu, M., Zhang, W., Tang, W., Wang, Y., Zhao, X., Wang, X., et al. Isocyclopamine, a novel synthetic derivative of cyclopamine, reverts doxorubicin resistance in MCF-7/ADR cells by increasing intracellular doxorubicin accumulation and downregulating breast cancer stem-like cells. Tumour Biol., 2015.
200. [200] Hu, K., Zhou, H., Liu, Y., Liu, Z., Liu, J., Tang, J., et al. Hyaluronic acid functional amphipathic and redox-responsive polymer particles for the co-delivery of doxorubicin and cyclopamine to eradicate breast cancer cells and cancer stem cells. Nanoscale 7 (2015), 8607–8618.
201. [201] Tamir, S., Eizenberg, M., Somjen, D., Izrael, S., Vaya, J., Estrogen-like activity of glabrene and other constituents isolated from licorice root. J. Steroid Biochem. Mol. Biol. 78 (2001), 291–298.
202. [202] Tamir, S., Eizenberg, M., Somjen, D., Stern, N., Shelach, R., Kaye, A., et al. Estrogenic and antiproliferative properties of glabridin from licorice in human breast cancer cells. Cancer Res. 60 (2000), 5704–5709.
203. [203] Hsu, Y.L., Wu, L.Y., Hou, M.F., Tsai, E.M., Lee, J.N., Liang, H.L., et al. Glabridin, an isoflavan from licorice root, inhibits migration, invasion and angiogenesis of MDA-MB-231 human breast adenocarcinoma cells by inhibiting focal adhesion kinase/Rho signaling pathway. Mol. Nutr. Food Res. 55 (2011), 318–327.
204. [204] Jiang, F., Li, Y., Mu, J., Hu, C., Zhou, M., Wang, X., et al. Glabridin inhibits cancer stem cell-like properties of human breast cancer cells: an epigenetic regulation of miR-148a/SMAd2 signaling. Mol. Carcinog., 2015.
205. [205] Seo, E.J., Wiench, B., Hamm, R., Paulsen, M., Zu, Y., Fu, Y., et al. Cytotoxicity of natural products and derivatives toward MCF-7 cell monolayers and cancer stem-like mammospheres. Phytomedicine 22 (2015), 438–443.
206. [206] Ranji, P., Salmani Kesejini, T., Saeedikhoo, S., Alizadeh, A.M., Targeting cancer stem cell-specific markers and/or associated signaling pathways for overcoming cancer drug resistance. Tumour Biol., 2016.
207. [207] Zhou, X., Wang, W., Li, P., Zheng, Z., Tu, Y., Zhang, Y., et al. Curcumin enhances the effects of 5-fluorouracil and oxaliplatin in inducing gastric cancer cell apoptosis both in vitro and In vivo. Oncol. Res. 23 (2016), 29–34.
208. [208] Buhrmann, C., Shayan, P., Kraehe, P., Popper, B., Goel, A., Shakibaei, M., Resveratrol induces chemosensitization to 5-fluorouracil through up-regulation of intercellular junctions, epithelial-to-mesenchymal transition and apoptosis in colorectal cancer. Biochem. Pharmacol. 98 (2015), 51–68.